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The epidemiology of colorectal cancer, including incidence, mor-
tality, age of onset, stage of diagnosis, and screening, varies re-
gionally among American Indians. The objective of the Improv-
ing Northern Plains American Indian Colorectal Cancer Screening
study was to improve understanding of colorectal cancer screen-
ing among health care providers serving Northern Plains Ameri-
can Indians.
Methods
Data were collected, in person, from a sample of 145 health care
providers at 27 health clinics across the Northern Plains from May
2011 through September 2012. Participants completed a 32-ques-
tion,  self-administered assessment designed to assess provider
practices, screening perceptions, and knowledge.
Results
The proportion of providers who ordered or performed at least 1
colorectal cancer screening test for an asymptomatic, average-risk
patient in the previous month was 95.9% (139 of 145). Of these
139 providers, 97.1% ordered colonoscopies, 12.9% ordered flex-
ible sigmoidoscopies, 73.4% ordered 3-card, guaiac-based, fecal
occult blood tests, and 21.6% ordered fecal immunochemical tests.
Nearly two-thirds (64.7%) reported performing in-office guaiac-
based fecal occult blood tests using digital rectal examination spe-
cimens.  Providers  who reported  receiving a  formal  update  on
colorectal cancer screening during the previous 24 months were
more likely to screen using digital rectal exam specimens than pro-
viders  who had received a formal  update on colorectal  cancer
screening more than 24 months prior (73.9% vs 56.9%, respect-
ively, χ2 = 4.29, P = .04).
Conclusion
Despite recommendations cautioning against the use of digital
rectal examination specimens for colorectal cancer screening, the
practice  is  common among providers  serving Northern  Plains
American Indian populations. Accurate up-to-date, ongoing edu-
cation for patients, the community, and health care providers is
needed.
Introduction
In 2012, more than 134,000 people were diagnosed with colorectal
cancer (CRC) in the United States (1). Approximately 70% to 75%
of those diagnosed with CRC are considered to be at average risk
for the disease (2).  Screening people at average risk decreases
CRC incidence and mortality (2,3). Screening and reduction of
identifiable risk factors have contributed to long-term declines in
CRC incidence since the mid-1980s (4).
CRC incidence, mortality, age of onset, and stage of diagnosis
vary regionally among American Indians and Alaska Natives (AI/
ANs), with higher rates of CRC in the Alaska, Northern Plains,
and Southern Plains regions (5). One study showed that AI/ANs
were younger at age of diagnosis and more likely to be diagnosed
with CRC at an advanced stage than whites (5). AI/ANs are less
likely than whites to be up to date with CRC screening (6–9). Ac-
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cording to data from the 2014 Government Performance and Res-
ults Act, 37.5% of AI/ANs nationally were up to date with CRC
screening (10). By comparison, in 2013, 58.2% of the general pop-
ulation of the United States was up to date with recommended
CRC screening, based on data from the National Health Interview
Survey (11).
Provider recommendation is an important determinant of whether
or not a patient undergoes CRC screening (12,13). Providers need
to be aware of the most current CRC screening recommendations
(14). One challenge to screening that remains among primary care
physicians is the practice of screening for occult fecal blood using
specimens obtained from digital rectal examinations (DREs), even
though this practice detects fewer than 5% of patients with CRC or
advanced adenomas (15,16). A web-based survey suggested that
screening by using DRE stool specimens is still pervasive among
Indian Health Service providers (17). A better understanding of
factors  that  influence  provider  screening  recommendations  is
needed to inform programs that encourage guideline-based screen-
ing practices. The Improving Northern Plains American Indian
Colorectal Cancer Screening (INPACS) study was undertaken to
improve understanding of CRC screening among health care pro-
viders serving Northern Plains American Indians.
Methods
The INPACS project was created to learn about CRC screening at
clinics serving American Indians across the Northern Plains and to
then  use  project  data  to  guide  the  development  of  clinical
strategies for improving screening practices and capacity.  The
American  Indian  Cancer  Foundation  invited  the  54  Northern
Plains  facilities  that  provide  health  care  services  primarily  to
American Indians to participate in the INPACS project. These fa-
cilities included a combination of Indian Health Service (IHS), tri-
bal, and urban American Indian health systems in the following
states:  Minnesota,  Montana,  Nebraska,  North  Dakota,  South
Dakota, Wisconsin, and Wyoming. All INPACS materials and in-
struments were reviewed and approved by the National Institution-
al Review Board (IRB) at Indian Health Service headquarters, the
IHS Great Plains Area IRB, and the Rocky Mountain Tribal IRB
of the Montana–Wyoming Tribal Leaders Council.
Sample and data collection
Data were collected in person by INPACS staff members from a
sample of 145 health care providers from 27 of the 54 health clin-
ics who agreed to participate. Data were collected from May 2011
through September 2012. The 90-minute INPACS program, which
included data collection through a self-administered provider as-
sessment followed by a continuing medical education course, was
scheduled during a typical clinic staff meeting to ensure high at-
tendance.  Attendees  learned  details  of  the  INPACS  program
through a verbal presentation and reading the informed consent
document. The purpose of the INPACS continuing medical educa-
tion course was twofold: first, to offer an incentive to providers to
compensate for their time away from clinic hours and second, to
support the clinic in being up to date on CRC screening practices
by their participation in the program. Eligible participants were
primary care providers who served American Indian adults: physi-
cians, nurse practitioners, physician assistants, and clinical nurse-
midwives who treated adult patients. The self-administered assess-
ment administered to providers did not include individual identifi-
ers, and clinic-specific data were confidential.
Self-administered provider assessment and
variables
After informed consent was obtained, participants completed a
self-administered provider assessment under supervision of the
INPACS staff. This assessment was designed to assess provider
screening practices, perceptions, and knowledge. The National
Cancer Institute’s National Survey of Primary Care Physicians’
Cancer Screening Recommendations and Practice for Breast, Cer-
vical, Colorectal, and Lung Cancer Screening was used to guide
the development of the self-administered provider assessment,
which included 32 questions (18). To assess the types of CRC
screenings that providers ordered or performed for their patients,
participants were asked the following question: “During a typical
month, how many times do you order or perform the following
screening tests for your asymptomatic, average-risk patients: 1)
guaiac of digital rectal exam (DRE) specimen, 2) take home 3-
card fecal occult blood tests (FOBT), 3) fecal immunochemistry
test  (FIT),  4)  screening  flexible  sigmoidoscopy,  5)  screening
colonoscopy, 6) other (specify).”
To discern variables that might influence CRC screening recom-
mendations, participants were asked the following: 1) “How many
years have you been in practice since finishing your training,” 2)
“When was the  last  time you received a  formal  update  (CME
course or in-service) on CRC screening,” and 3) “To what extent
do the following influence your recommendation for CRC screen-
ing for your patients: a) US Preventive Services Task Force re-
commendations,  b)  American  Cancer  Society/multi-society
guidelines [guidelines issued by the American Cancer Society, the
US Multi-Society  Task  Force  on  Colorectal  Cancer,  and  The
American College of Radiology], c) whether the patient has third-
party insurance, including Medicare and Medicaid, d) availability
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of screening tests (other than FOBT), e) how others in my prac-
tice or local community provide CRC screening for their patients,
f) my patients’ preferences for CRC screening, and g) the availab-
ility of IHS or tribal funds for screening.” We used χ2 tests to ex-
amine differences in categorical data and considered significance
at P < .05. Analyses were conducted using Epi Info 7 (19).
We hypothesized that providers who began practice before 2008
would be more likely to order or perform in-office FOBTs using a
digital rectal exam (DRE) specimen for screening than providers
who started practicing in 2008 or later. The year 2008 was used as
the cutoff because that was the year in which updated CRC screen-
ing recommendations were released by the US Preventive Ser-
vices Task Force and a joint guideline was issued by the Ameri-
can  Cancer  Society,  the  US  Multi-Society  Task  Force  on
Colorectal Cancer, and The American College of Radiology (14).
We also hypothesized that providers who had received a formal
update on CRC screening during the previous 24 months would be
less likely to order or perform FOBT by using a DRE specimen as
a screening test than providers who had received a formal update
on CRC screening more than 24 months ago.
Results
The proportion of providers who ordered or performed at least one
CRC screening test for an asymptomatic, average-risk patient in
the previous month was 95.9% (139 of 145). Of the 139 providers,
97.1% (n = 135) ordered screening colonoscopies, 12.9% (n = 18)
ordered  screening  flexible  sigmoidoscopies,  73.4% (n  =  102)
ordered take-home 3-card FOBT, 21.6% (n = 30) ordered fecal
immunochemical tests, and 64.7% (n = 90) ordered or performed
office-based FOBT using DRE specimens. The number of times
per month any given provider ordered or performed a particular
CRC screening test for their asymptomatic, average-risk patients is
presented in Table 1.
A similar proportion of providers who began practice in 2008 or
later reported ordering or performing an office-based FOBT using
a DRE specimen compared with those who began practice before
2008 (69.6% vs 63.8%, respectively;  χ2  = 0.28,  P = .60).  Pro-
viders who reported receiving a formal update on CRC screening
during the previous 24 months were more likely to  perform a
FOBT using DRE specimens than providers who had received a
formal  update  on  CRC screening  more  than  24  months  prior
(73.9% vs 56.9%, respectively; χ2 = 4.29, P = .04).
When stratifying by type of provider, mid-level providers (nurse
practitioners, physician assistants, certified nurse-midwives) were
more likely than physicians to have begun practice in 2008 or later
(24.6%  vs  9.5%,  respectively,  χ2  =  5.76,  P  =  .02)  (Table  2).
However, mid-level providers were less likely to have received a
formal update on CRC screening during the previous 24 months
than physicians (36.9% vs 58.1%, respectively, χ2 = 6.22, P = .01).
A similar proportion of mid-level providers ordered or performed
an office-based  FOBT using  a  DRE specimen compared  with
physicians (63.1% vs 66.2%, respectively; χ2 = 0.15 P = .70) (Ta-
ble 2). We also found no particular method of CRC screening that
mid-level providers recommended more than physicians.
Most providers reported that US Preventive Services Task Force
recommendations were very influential or somewhat influential in
their screening recommendations (98.5%) followed by American
Cancer Society/Multi-Society guidelines (94.1%) (Table 3). The
patient’s preference for the type of test was also influential for
most providers (89.7%), although 30.2% of providers reported that
patients frequently preferred the provider to choose the appropri-
ate test for them. The availability of IHS or tribal funds for screen-
ing influenced the tests ordered or performed by 69.6% of pro-
viders. Finally, third party medical coverage (private insurance,
Medicare and Medicaid) was reported by 40.4% of providers to in-
fluence their  CRC screening decisions.  The influence various
screening guidelines and other factors had on screening recom-
mendations did not vary significantly by provider type (Table 3).
Discussion
Provider adherence to evidence-based screening practices is neces-
sary for CRC prevention and control. This study focused on the
CRC  screening  practices  of  145  practitioners  who  served  at
American Indian health facilities in the Northern Plains. Although
most providers in our sample reported offering CRC screening,
adherence  to  guidelines  on  recommended  screening  practices
could be improved. Sixty-five percent of our sample used DRE
stool specimens for in-office FOBTs among their CRC screening
options. These findings are consistent with the findings of a previ-
ous survey of IHS and tribal health providers in which 23.0% of
providers who screened with FOBT recommended only in-office
FOBT specimens (17) and a survey of providers nationwide that
showed that 32.5% used in-office FOBT as their only method of
CRC screening (20). The use of DRE stool specimens for FOBT
did not vary significantly by the length of time providers had been
in practice. Counterintuitively, providers who reported receiving
education on CRC screening recommendations in the previous 24
months were more likely to report using DRE stool specimens to
complete an in-office FOBT.
The guaiac-based testing of DRE samples was recommended by
most medical societies as a CRC screening test in the 1980s and
1990s (21,22) and as such was commonly taught in medical train-
ing  programs.  However,  data  from a  study published  in  2005
found the practice to have a sensitivity for advanced neoplasia
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(cancer or advanced adenomatous polyps) of only 4.9% (15). Con-
cerns that such testing may give patients and practitioners false as-
surance about cancer status and dissuade more appropriate screen-
ing led professional societies in the mid-1990s to urge abandon-
ment of the practice (23).
Although this study centered on self-administered provider assess-
ments, focus groups conducted with providers in another compon-
ent of the INPACS program found suboptimal awareness that the
use of a single stool sample on a FOBT card after a DRE was no
longer a recommended screening test. Many factors emerged dur-
ing the focus groups that may help explain the continuation of this
practice. Among these, focus group participants often cited their
low expectations for patients completing other forms of screening.
Pressure to increase screening rates to meet targets set by the Gov-
ernment Performance Results Act also played a role for some. Fi-
nally, many participants reported being told by health administrat-
ors to “at least do a DRE test.” The finding that study participants
who reported having received continuing medical education or
some other update on CRC screening in the previous 24 months
were more likely to conduct DRE screening suggests that those
tasked with conducting provider education may not be communic-
ating clearly  that  these  practices  are  no longer  recommended.
Strategies that may help to discourage DRE in practice include de-
velopment of a clinic policy of recommended screenings and fre-
quent continuing medical education on updated CRC screening.
Although national recommendations were the most commonly
cited influence on screening practices reported by providers, pa-
tient preference and socioeconomic factors were also cited. For al-
most half of the providers (40.4%) a recommendation for CRC
screening was influenced by the availability of health insurance
coverage. Moreover, the availability of IHS or tribal funds for
screening influenced the  majority  (69.6%) of  providers’  CRC
screening recommendations. Funding restrictions may also be af-
fecting the community’s ability to pursue new screening options.
This may explain why DRE and take home 3-card FOBT and are
being performed more frequently than FIT.
Access to CRC screening for American Indians can be particu-
larly challenging. Health care coverage is complex, consisting of a
mixture of IHS, tribal, public, and commercial payers. According
to the Institute of Medicine, IHS is underfunded and unable to
meet the needs of the population it serves (24). One possible res-
ult of underfunding may be rationing of noncritical services such
as screening colonoscopy. Tribal health systems vary widely in the
resources available them, often being primarily influenced by the
success of tribal gaming and other business enterprises. Factors
such as tribal enrollment, tribal employment, and county of resid-
ence may all affect the health services available to American Indi-
ans.
The Affordable Care Act could provide American Indians with
more choices that could lead to more adequate health insurance
coverage. Depending on eligibility and the coverage available,
American Indians can continue to use IHS, tribal, or urban Indian
health  programs,  enroll  in  a  qualified  health  plan through the
Health Insurance Marketplace, or access coverage through Medi-
care or Medicaid (25). Whether the further removal of financial
barriers to CRC screening will affect screening uptake remains to
be seen.
In addition to cost, many other barriers to endoscopic screening
(colonoscopy, sigmoidoscopy) for CRC may influence provider
recommendations. Many tribal health systems are located far from
endoscopy services that can provide screening or follow-up pro-
cedures.  In  addition to  travel,  other  barriers  are  low levels  of
health literacy about screening benefits, fear of embarrassment or
findings, traditional health beliefs, and mistrust of medical prac-
tices that do not serve primarily American Indians (26–28).  A
solution that may improve screening capacity may be to fully im-
plement FIT testing with an adequate tracking and follow-up sys-
tem and to keep colonoscopy referrals to a minimum by reserving
colonoscopy for those with positive FIT results.
The American College of Physicians guidelines reinforce the im-
portance of shared decision making between provider and patient
(29). Shared decision making involves the provider discussing the
pros and cons of CRC screening options with the patient and then
assisting the patient in selecting the most appropriate test the pa-
tient is willing and able to complete. Despite apparent efforts to
share decision making, many providers from our survey (30.2%)
reported their patients often wanted them to choose a test for them.
Work to validate this impression from the patient’s perspective is
needed.
A limitation of the INPACS study is that the provider assessment
was self-administered and allowed for over- or under-reporting of
provider behaviors on CRC screening recommendations and prac-
tices. Another limitation of the study is the low participation rate.
Although the study team visited 40 of the 54 health clinics serving
American Indians in the Northern Plains, the 145 survey parti-
cipants were the health care providers from 27 clinics that particip-
ated in both components of the study (facility assessment and pro-
vider assessment). The results of this study are also limited in their
generalizability because they are specific to American Indian clin-
ics in the Northern Plains.
Disparities in CRC incidence,  mortality,  and screening among
Northern Plains American Indians emphasize the need to better
understand the barriers this population faces in CRC prevention
and control. DRE use is often based on the perception that it may
be the only opportunity to screen the patient, even though it is not
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a best practice and may lead to incorrect results. The continued use
of this test points out the critical need to deliver up-to-date, ongo-
ing provider and patient education in American Indian health sys-
tems to ensure this population’s health providers practice in con-
cordance with national  CRC screening recommendations.  The
Centers for Disease Control and Prevention offers free online con-
tinuing medical education on CRC screening for providers (30).
After completing the self-administered provider assessment for
this study, all providers participated in a continuing medical edu-
cation session that reviewed current CRC screening recommenda-
tions  that  included  data  on  why  screening  using  office-based
FOBT with DRE sample is discouraged. Educating patients and
the community is equally important. Accurate, up-to-date, ongo-
ing education for patients, the community, and health care pro-
viders  is  needed.  Resolving  the  issue  of  up-to-date  provider
screening recommendations is a critical step, but much work will
be needed to address the economic and sociocultural barriers that
hinder effective CRC prevention and control in this population.
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Tables
Table 1. Number of Times Health Care Providers (N = 139) Ordered or Performed a Colorectal Screening Test for Asymptomatic, Average-Risk Patients During a Typ-
ical Month, Northern Plainsa American Indians, May 2011–September 2012
Test
No. (%) of Health Care Providers, by Times per  Month Test Performed or Ordered
0 Times 1–10 Times 11–20 Times 21–40 Times >40 Times
Guaiac of digital rectal examination (DRE) specimen 49 (35.3) 85 (61.2) 2 (1.4) 2 (1.4) 1 (0.7)
Take home 3-card fecal occult blood test 37 (26.6) 80 (57.6) 17 (12.2) 4 (2.9) 1 (0.7)
Fecal immunochemistry test 109 (78.4) 20 (14.4) 2 (1.4) 5 (3.6) 3 (2.2)
Screening flexible sigmoidoscopy 121 (87.1) 16 (11.5) 1 (0.7) 1 (0.7) 0 (0.0)
Screening colonoscopy 4 (2.9) 112 (80.6) 15 (10.8) 6 (4.3) 2 (1.4)
a Includes Minnesota, Montana, Nebraska, North Dakota, South Dakota, Wisconsin, and Wyoming. Data are from the Improving Northern Plains American Indian
Colorectal Cancer Screening project.
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Table 2. Influences and Practices of Physicians and Mid-Level Health Care Providers (N = 139) Serving Northern Plainsa American Indians Regarding Colorectal
Cancer Screening, by Type of Provider, May 2011–September 2012
Characteristic
Type of Health Care Provider
MD/DO (n = 74), n (%) NP/PA/CNM (n = 65), n (%) P Valueb
Began clinical practice 2008 or later 7 (9.5) 16 (24.6) .02
≤24 Months since last CRC training 41 (55.4) 24 (36.9) .01
Screening tests recommended
Screening colonoscopy 70 (94.6) 65 (100.0) .06
Screening flexible sigmoidoscopy 12 (16.2) 6 (9.2) .22
Take home 3-card fecal occult blood test 51 (68.9) 51 (78.5) .21
Fecal immunochemistry test 18 (24.3) 12 (18.5) .40
Guaiac of digital rectal examination specimen 49 (66.2) 41 (63.1) .70
Abbreviations: CNM, certified nurse-midwife; CRC, colorectal cancer; DO, doctor of osteopathy; MD, medical doctor; NP, nurse practitioners; PA, physician assistant.
a Includes Minnesota, Montana, Nebraska, North Dakota, South Dakota, Wisconsin, and Wyoming. Data are from the Improving Northern Plains American Indian
Colorectal Cancer Screening project.
b Determined by χ2 test.
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Table 3. Factors Influencing Health Care Providers’ (N = 139) Colorectal Cancer Screening Practices for Northern Plainsa American Indians, by Level of Influence




Very Influential Somewhat Influential Not Influential
P Valuebn (%)
US Preventive Services Task Force recommendations 133 96 (72.2) 35 (26.3) 2 (1.5) —
MD/DO 72 49 (68.1) 22 (30.6) 1 (1.4) .48
NP/PA/CNM 61 47 (77.1) 13 (21.3) 1 (1.6)
American Cancer Society/multi-society guidelinesc 135 93 (68.9) 34 (25.2) 8 (5.9) —
MD/DO 73 49 (67.1) 20 (27.4) 4 (5.5) .80
NP/PA/CNM 62 44 (71.0) 14 (22.6) 4 (6.5)
Whether the patient has third party insurance, including
Medicare and Medicaid
136  18 (13.2) 37 (27.2)  81 (59.6) —
MD/DO 73 10 (13.7) 21 (28.8) 42 (57.5) .87
NP/PA/CNM 63 8 (12.7) 16 (25.4) 39 (61.9)
Availability of screening tests (other than FOBT) 135 43 (31.9) 58 (43.0) 34 (25.2) —
MD/DO 72 27 (37.5) 31 (43.1) 14 (19.4) .17
NP/PA/CNM 63 16 (25.4) 27 (42.9) 20 (31.8)
How others in my practice or local community provide
CRC screening for their patients
135 13 (9.6) 56 (41.5) 66 (48.9) —
MD/DO 72 7 (9.7) 31 (43.1) 34 (47.2) .91
NP/PA/CNM 63 6 (9.5) 25 (39.7) 32 (50.8)
My patients’ preferences for CRC screening (n = 135) 135 36 (26.7) 85 (63.0) 14 (10.4)
MD/DO 73 17 (23.3) 47 (64.4) 9 (12.3) .52
NP/PA/CNM 62 19 (30.7) 38 (61.3) 5 (8.1)
Availability of IHS or tribal funds for screening 135 47 (34.8) 47 (34.8) 41 (30.4) —
MD/DO 73 26 (35.6) 23 (31.5) 24 (32.9) .65
NP/PA/CNM 62 21 (33.9) 24 (38.7) 17 (27.4)
Abbreviations: CNM, certified nurse-midwife; CRC, colorectal cancer; DO, doctor of osteopathy; DRE, digital rectal exam; IHS, Indian Health Service; MD, medical
doctor; NP, nurse practitioners; PA, physician’s assistant; —, not applicable.
a Includes Minnesota, Montana, Nebraska, North Dakota, South Dakota, Wisconsin, and Wyoming. Data are from health care providers surveyed for the Improving
Northern Plains American Indian Colorectal Cancer Screening project.
b Difference between level of influence and type of provider determined by χ2 test.
c Guidelines issued by the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and The American College of Radiology (14).
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